Form 4: Kiniksa Pharmaceuticals Executive Ross Moat Sells Shares Under 10b5-1 Plan

Chief Commercial Officer Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals International, plc under a pre-arranged 10b5-1 trading plan.

Summary

• On April 21, 2025, Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, sold 18,259 Class A Ordinary Shares.
• The sale was executed at a weighted average price of $20.29 per share, with individual trades occurring between $20.05 and $20.53.
• The transaction was conducted under a 10b5-1 trading plan established on May 3, 2024.
• Following the transaction, Moat directly owns 9,415 shares of Kiniksa Pharmaceuticals International, plc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a transaction under a pre-existing 10b5-1 plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on inside information at the time of the transaction.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Ross Moat, share sale, Form 4, 10b5-1 plan, KNSA, Chief Commercial Officer, insider trading